Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Alliance for International Medical Action | University of Bordeaux | Bernhard Nocht Institute for Tropical Medicine | Federal Medical Centre, Owo | Programme PAC-CI | Fondation Recherche Scientifique Benin | Médecins Sans Frontières Belgium | Alex Ekwueme
Deal Size : Inapplicable
Deal Type : Inapplicable
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2024
Lead Product(s) : Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Alliance for International Medical Action | University of Bordeaux | Bernhard Nocht Institute for Tropical Medicine | Federal Medical Centre, Owo | Programme PAC-CI | Fondation Recherche Scientifique Benin | Médecins Sans Frontières Belgium | Alex Ekwueme
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Vir Biotechnology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 01, 2023
Lead Product(s) : Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Vir Biotechnology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ribavirin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 08, 2022
Lead Product(s) : Ribavirin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Ankara City Hospital Bilkent | Istanbul Umraniye Training and Research Hospital | Koç University | Monitor CRO
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 02, 2021
Lead Product(s) : Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Ankara City Hospital Bilkent | Istanbul Umraniye Training and Research Hospital | Koç University | Monitor CRO
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lopinavir,Ribavirin,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Triple Drug Combination Shows Promise in Covid-19 Treatment
Details : Trial revealed that patients treated with triple drug combination (lopinavir–ritonavir and ribavirin) tested negative for COVID-19 five days earlier than those treated with lopinavir–ritonavir alone.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2020
Lead Product(s) : Lopinavir,Ribavirin,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Virazole
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 16, 2020
Lead Product(s) : Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Virazole
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 22, 2020
Lead Product(s) : Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The company believes that since ribavirin is a synthetic nucleoside, It may work to stop viral replication and VIRAZOLE may be effective in reducing the severity of COVID-19 infection.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 14, 2020
Lead Product(s) : Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 06, 2016
Lead Product(s) : Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Weihai Rensheng Pharmacy
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Xiaoer Jiebiao Oral Liquid on Hand-foot-mouth Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 31, 2014
Lead Product(s) : Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Weihai Rensheng Pharmacy
Deal Size : Inapplicable
Deal Type : Inapplicable